Metal-based anticancer chemotherapeutic agents

Area of Science:

• Medicinal Chemistry
• Inorganic Chemistry
• Oncology

Background:

• The discovery of cisplatin's antitumor activity spurred research into metal-based chemotherapy agents.
• Significant advancements have been made over four decades, with numerous metal complexes evaluated in vitro and in vivo.
• Several metal complexes are currently in various stages of clinical trials.

Purpose of the Study:

• To review recent progress in the rational design of novel metal-based anticancer agents.
• To highlight metal complexes that address limitations of current chemotherapy drugs, including toxicity and resistance.
• To explore innovative metal complexes with potential for enhanced efficacy and improved pharmacological profiles.

Main Methods:

• Review of recent scientific literature on metal-based anticancer agents.
• Focus on platinum (Pt(IV), Pt(II)), ruthenium (Ru(II), Ru(III)), gold (Au(I), Au(III)), and titanium (Ti(IV)) complexes.
• Analysis of novel complex designs, including Pt(IV) prodrugs, polynuclear Pt(II) complexes, anti-metastatic Ru complexes, and Au/Ti antitumor agents.

Main Results:

• Recent progress includes Pt(IV) prodrugs activated within tumor cells.
• Polynuclear Pt(II) complexes exhibit unique DNA binding capabilities.
• Development of anti-metastatic Ru(II)/Ru(III) complexes and antitumor Au(I)/Au(III) and Ti(IV) complexes.

Conclusions:

• Novel metal complexes show promise in overcoming current chemotherapy challenges.
• Continued research focuses on enhancing drug efficacy and reducing side effects.
• Metal-based agents represent a vital area for future cancer treatment strategies.